Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001058116 | SCV001222660 | uncertain significance | Multiple endocrine neoplasia, type 1 | 2023-09-05 | criteria provided, single submitter | clinical testing | This sequence change replaces threonine, which is neutral and polar, with isoleucine, which is neutral and non-polar, at codon 292 of the MEN1 protein (p.Thr292Ile). This variant is present in population databases (rs780646691, gnomAD 0.0009%). This variant has not been reported in the literature in individuals affected with MEN1-related conditions. ClinVar contains an entry for this variant (Variation ID: 853328). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt MEN1 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV002374938 | SCV002686237 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-08-26 | criteria provided, single submitter | clinical testing | The p.T292I variant (also known as c.875C>T), located in coding exon 5 of the MEN1 gene, results from a C to T substitution at nucleotide position 875. The threonine at codon 292 is replaced by isoleucine, an amino acid with similar properties. This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |